Literature DB >> 16522701

Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.

Libuse Tauchmanovà1, Rosario Pivonello, Carolina Di Somma, Riccardo Rossi, Maria Cristina De Martino, Luigi Camera, Michele Klain, Marco Salvatore, Gaetano Lombardi, Annamaria Colao.   

Abstract

INTRODUCTION: The effects of endogenous cortisol (F) excess on bone mass and vertebral fractures have still not been thoroughly investigated. The aim of this cross-sectional case-control study was to investigate factors influencing bone demineralization and vertebral fractures in different conditions of F excess, i.e. Cushing's disease and adrenal and ectopic Cushing's syndrome.
MATERIALS AND METHODS: Eighty consecutive patients and 80 controls were prospectively enrolled: 37 patients (21 females) with pituitary ACTH-secreting adenoma, 18 (14 females) with adrenocortical adenoma, 15 (11 females) with adrenal carcinoma of mixed secretion, and 10 (three females) with ectopic ACTH secretion. The groups had similar age. At diagnosis, bone mineral density (BMD) was determined by the dual-energy x-ray absorptiometry technique at the lumbar spine (L1-L4) and femoral neck; vertebral fractures were investigated by standard spinal radiographs.
RESULTS: When comparing the groups with different etiology of F excess, the patients with ectopic ACTH secretion had higher F and lower BMD values than the other subgroups. Morning F (P = 0.03) and testosterone levels (P = 0.04) correlated with lumbar BMD. Vertebral fractures were found in 61 (76%) of the patients, were multiple in 52 (85%) of the cases, and clinically evident in 32 (52%). Only multiple fractures were more frequent in patients with ectopic ACTH hypersecretion (P < 0.05). Lumbar spine BMD was the best predictor of vertebral fractures (P < 0.01). Surprisingly, amenorrheic and eumenorrheic women had similar BMD values and fracture prevalence.
CONCLUSION: A high prevalence (76%) of vertebral fracture was revealed, regardless of the etiology of the patients' hypercortisolism. The harmful effects of F excess at the spine were partly counterbalanced by the increased androgen production but were not affected by gonadal status in women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522701     DOI: 10.1210/jc.2005-0582

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants.

Authors:  L Trementino; G Appolloni; L Ceccoli; G Marcelli; C Concettoni; M Boscaro; G Arnaldi
Journal:  Osteoporos Int       Date:  2013-10-15       Impact factor: 4.507

Review 2.  Glucocorticoid-induced osteoporosis and osteonecrosis.

Authors:  Robert S Weinstein
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-23       Impact factor: 4.741

3.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

4.  An unusual case of hypercortisolism with multiple weight-bearing bone fractures.

Authors:  Georgios Papadakis; Brigitte Uebelhart; Michel Goumaz; Sophie Zawadynski; Rene Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

5.  High bone marrow fat in patients with Cushing's syndrome and vertebral fractures.

Authors:  Francesco Ferraù; Salvatore Giovinazzo; Erika Messina; Agostino Tessitore; Sergio Vinci; Gherardo Mazziotti; Andrea Lania; Francesca Granata; Salvatore Cannavò
Journal:  Endocrine       Date:  2019-08-02       Impact factor: 3.633

6.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

7.  Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.

Authors:  Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov
Journal:  Osteoporos Int       Date:  2013-01-29       Impact factor: 4.507

8.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

9.  Cushing's syndrome in type 2 diabetes patients with poor glycemic control.

Authors:  Askin Gungunes; Mustafa Sahin; Taner Demirci; Bekir Ucan; Evrim Cakir; Muyesser Sayki Arslan; Ilknur Ozturk Unsal; Basak Karbek; Mustafa Calıskan; Mustafa Ozbek; Erman Cakal; Tuncay Delibasi
Journal:  Endocrine       Date:  2014-04-17       Impact factor: 3.633

Review 10.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.